A twice-a-day pill for the most common type of advanced breast cancer has been approved on the NHS in what scientists say is a “landmark moment”.
Around 1,100 – and potentially up to 3,000 – women every year could benefit from capivasertib for hormone receptor (HR)-positive HER2-negative breast cancer that has certain genetic mutations and has spread.
